Please login to the form below

Not currently logged in

US FDA approves Roche's assay as first blood test to diagnose diabetes

Will help catch diabetes early in country where seven million people are undiagnosed

US FDA approves Roche's assay as first blood test to diagnose diabetes

Doctors in the US will have a new tool to help tackle the growing epidemic of diabetes after the FDA approved Roche's assay as the first blood sugar test to diagnose the condition.

Roche's Cobas Integra 800 Tina-quant HbA1cDx assay and other similar tools to measure blood sugar are already used to monitor the glucose control of people with diabetes, but this is the first time the FDA has cleared this method as a diagnosis test.

The approval reflects the evolving nature of diabetes diagnosis, with the FDA noting that many healthcare professionals, influenced by recommendations from experts, are already using HbA1c tests, which measure the patient's average glucose level over a three-month period, to diagnose diabetes.

There is a difficulty in knowing which HbA1c tests are accurate enough for this purpose, however, and the FDA backing will boost confidence in Roche's assay.

“Providing healthcare professionals with another tool to identify undiagnosed cases of diabetes should help them provide patients appropriate guidance on treatment before problems develop,” said Dr Alberto Gutierrez, director of the Office of In Vitro Diagnostics and Radiological Devices at FDA's Center for Devices and Radiological Health.

Diabetes is a major health problem in the US, where 25.8 million people (about 8 per cent of the population) are estimated to live with the condition.

This includes about seven million people who remain undiagnosed, and the approval of Roche's device will boost existing diagnostic efforts that currently include a fasting blood glucose test and an oral glucose tolerance test.

The FDA said the Tina-quant HbA1cDx assay demonstrated its ability in a trial involving 141 blood samples.

The experiment found there was less than a six per cent difference in the accuracy of test results from the Roche's assay compared to results from the standard reference for haemoglobin analysis.

24th May 2013

From: Sales, Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
GCI Health

We are GCI Health, one of the world’s largest specialist healthcare communications agencies with global hubs in London and New...

Latest intelligence

What is a patient-centric brand anyway?
It’s hard to believe that in our industry, there have been ongoing rumblings about patient-centricity for years now. Sure, there are some great companies who have worked hard to bring...
‘Less Is More: Making Patient-Centered Digital Communication a Reality’
Letizia Affinito writes on the Gower Publishing blog....
The Seven Cs Of Cross-Functional Brand Planning
As more and more organisations have moved to cross-functional and cross-regional involvement in the development of their strategic and operational brand plans, the result has been greater engagement and alignment,...